Neoadjuvant Pembrolizumab and Lenvatinib for Mucosal Melanoma
Status:
Not yet recruiting
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
In many cancers, early stage diagnosis and early treatment offers the best chance of a
prolonged recurrence free- and overall survival. Neoadjuvant immunotherapy involves
administering immune checkpoint inhibitors before surgical resection in high-risk resectable
disease, such as mucosal melanoma. In resectable cancers, immune checkpoint inhibitors can
enhance anti-tumour immunity by exploiting a competent immune system prior to surgery.
Activating antigen-specific T cells found in the primary or baseline tumour continue to exert
anti-tumour effects on remaining neoplastic cells after the resection of the original tumour,
potentially preventing recurrences from occurring.
In resectable mucosal melanoma, an opportunity exists to improve clinical outcomes with the
addition of neoadjuvant and adjuvant systemic therapy with nivolumab and lenvatinib as an
adjunct to surgery.